Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Delayed radical prostatectomy not linked to adverse oncological outcomes

Key clinical point: Delayed radical prostatectomy does not appear to adversely affect oncologic outcomes for intermediate- and high-risk prostate cancer.

Major finding: Surgical delay was not significantly associated with upgrading on final pathology (odds ratio [OR], 0.98; P = .3), lymph-node invasion (OR, 0.88; P = .07), pathological locally advanced disease (OR, 1.0; P = .8), or need for adjuvant therapy (OR, 0.96; P = .6).

Study details: The data come from a study of 926 men undergoing radical prostatectomy across Europe for intermediate- and high-risk prostate cancer.

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Citation:

Diamand R et al. World J Urol. 2020 Aug 10. doi: 10.1007/s00345-020-03402-w.